SCHEMBL21069092

SCHEMBL21069092

CCOC(=O)NC(=S)Nc1nc(OCC(F)(F)F)ccc1C(C)(C)O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 1/20 0.41
▸ TSHR P16473 2/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ TP53 P04637 1/20 0.35
▸ HTT P42858 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ HPGDS O60760 1/20 0.35
▸ GAA P10253 3/20 0.34
▸ SMN1; SMN2 Q16637 3/20 0.34
▸ NPC1 O15118 2/20 0.34
▸ RAB9A P51151 1/20 0.34
▸ POLB P06746 1/20 0.34
▸ L3MBTL1 Q9Y468 2/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ UGCG Q16739 1/20 0.34
▸ HPGD P15428 2/20 0.33
▸ AAK1 Q2M2I8 1/20 0.33
▸ KDM4E B2RXH2 1/20 0.33
▸ LMNA P02545 2/20 0.33
▸ PDE5A O76074 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21108337 0.87 MAPT (0.41) MAPTTSHRMEN1TP53HTT
SCHEMBL21068978 0.84 MAPT (0.39) MAPTTSHRMEN1TP53HTT
SCHEMBL21068979 0.84 MAPT (0.39) MAPTTSHRMEN1TP53HTT
SCHEMBL21069203 0.79 MAPK8 (0.49) MAPTMEN1HTTKMT2AGAA
SCHEMBL18952675 0.79 MAPT (0.43) MAPTTSHRMEN1TP53HTT
SCHEMBL23628522 0.78 MAPT (0.39) MAPTTSHRMEN1TP53HTT
SCHEMBL28767431 0.78 HPGDS (0.36) MEN1KMT2AHPGDSSMN1; SMN2NPC1
SCHEMBL21108585 0.78 MAPT (0.39) MAPTTSHRMEN1TP53HTT
SCHEMBL18952492 0.77 ALDH1A1 (0.45) MAPTTSHRMEN1HTTKMT2A
SCHEMBL18952606 0.76 MAPT (0.39) MAPTTSHRKMT2AGAASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3475279-B1 TRIAZOLOPYRIDINES AS GAMMA-SECRETASE MODULATORS HOFFMANN LA ROCHE (CH) 2021-07-14 — — EP disclosed
EP-3475279-B1 TRIAZOLOPYRIDINES AS GAMMA-SECRETASE MODULATORS HOFFMANN LA ROCHE (CH) 2021-07-14 — — EP disclosed
US-10875854-B2 Triazolopyridines HOFFMANN-LA ROCHE INC. (US) 2020-12-29 — — US disclosed
US-10875854-B2 Triazolopyridines HOFFMANN-LA ROCHE INC. (US) 2020-12-29 — — US disclosed
US-20190194183-A1 TRIAZOLOPYRIDINES HOFFMANN-LA ROCHE INC. (US) 2019-06-27 — — US disclosed
US-20190194183-A1 TRIAZOLOPYRIDINES HOFFMANN-LA ROCHE INC. (US) 2019-06-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190194183-A1 TRIAZOLOPYRIDINES HTR2A, APP, PTGDR MAPT 185/4885TSHR 1566/4885MEN1 1958/4885
US-10875854-B2 Triazolopyridines HTR2A, APP, PTGDR MAPT 185/4885TSHR 1566/4885MEN1 1958/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback